Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
This is an international, randomized, open-label, controlled, multicenter phase II clinical trial to investigate and compare the safety and efficacy of palbociclib combined with fulvestrant or letrozole in women with ER+, HER2- locally advanced or metastatic breast cancer.
Metastatic Breast Cancer
DRUG: Palbociclib|DRUG: Fulvestrant|DRUG: Letrozole
1-year Progression Free Survival, Percentage of patients who are alive and without evidence of tumor progression (defined using RECIST v1.1), One year
Number of Participants With Grade 3/4 Adverse Events, SAEs, Deaths and Discontinuations â€¢, Grade 3/4 adverse events, SAEs, deaths and discontinuations following the CTCAE v5 criteria, Through study completion. From baseline up to 51 months.|Time To Progression (TTP), Time from randomization to disease progression, Through study completion. From baseline up to 51 months.|Overall Survival (OS), Time from date of randomization to date of death due to any cause, Through study completion. From baseline up to 51 months.|Clinical Benefit Rate, Percentage of patients who experience a CR, PR or stable disease (for at least 24 weeks) and assessed by modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria., Through study completion. From baseline up to 51 months.|Overall Response Rate, Proportion of patients with best overall response of confirmed complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST criteria guidelines (version 1.1), Through study completion. From baseline up to 51 months.
Patients will be stratified by site of disease (visceral vs. non-visceral) and by onset of metastatic disease diagnose (patients metastatic de novo versus non de novo).